Avalyn Pharma (NASDAQ:AVLN) Insider Sells 53,454 Shares of Company Stock

Avalyn Pharma Inc. (NASDAQ:AVLN) insider Fmr Llc sold 53,454 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $30.21, for a total transaction of $1,614,845.34. Following the sale, the insider directly owned 2,056,081 shares of the company’s stock, valued at approximately $62,114,207.01. The trade was a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Fmr Llc also recently made the following trade(s):

• On Monday, November 9th, Fmr Llc sold 175,000 shares of Avalyn Pharma stock. The shares were sold at an average price of $29.07, for a total value of $5,087,250.00.

Avalyn Pharma Trading Down 3.6%

Shares of Avalyn Pharma stock traded down $1.13 on Thursday, hitting $30.49. 185,254 shares of the company traded hands, compared to its average volume of 338,945. The company’s 50-day simple moving average is $28.87. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.35 billion and a P/E ratio of -1.34. Avalyn Pharma Inc. has a 12-month low of $22.24 and a 12-month high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.03). Analysts predict that Avalyn Pharma Inc. will post -3.86 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Avalyn Pharma in a report on Wednesday. Raymond James Financial assumed coverage on Avalyn Pharma in a report on Friday, October 2nd. They issued an “outperform” rating and a $60.00 target price on the stock. Wall Street Zen downgraded Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Morgan Stanley increased their price target on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma during the 2nd quarter worth approximately $1,321,000. Montanova Capital LLC acquired a new stake in shares of Avalyn Pharma in the second quarter valued at approximately $82,402,000. State Street Corp acquired a new stake in shares of Avalyn Pharma in the second quarter valued at approximately $10,501,000. Braidwell LP purchased a new position in Avalyn Pharma during the second quarter worth approximately $26,382,000. Finally, Profund Advisors LLC acquired a new position in Avalyn Pharma during the third quarter worth $668,000.

About Avalyn Pharma

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.